Advertisement

Outcomes After HPV Vaccination

  • Xavier Bosch José
Chapter
Part of the Practical Issues in Geriatrics book series (PIG)

Abstract

Human papillomavirus (HPV) is one of several hundred viruses comprising the Papillomaviridae family, of which at least 13 types are known to be responsible for cervical and other anogenital and oropharyngeal cancers. There is a large body of evidence substantiating the causal role of certain high-risk subtypes of HPV in the development of cervical cancer. Since persistent (>5 years) HPV infection with one of the high-risk genotypes has been proven to be a prerequisite for the development of HPV-related cancers, prophylactic vaccines have been developed in recent years to prevent against the future development of cancer or its precursors. The vaccines contain no live biological products or viral DNA and, thus, do not cause active infection. Since HPV vaccination started to be included in national vaccination policies, evidence has accumulated showing a significant positive impact of HPV vaccination against genital warts, cervical abnormalities, and HPV prevalence. Side effects of HPV vaccination are minor and infrequent. Scientific evidence of HPV vaccination efficacy is reviewed here, and perspectives for the future are addressed.

Keywords

Human papillomavirus HPV Cervical cancer Genital warts Vaccination 

References

  1. 1.
    Malik H, Khan FH, Ahsan H. Human papillomavirus: current status and issues of vaccination. Arch Virol. 2014;159:199–205.CrossRefGoogle Scholar
  2. 2.
    Arbyn M, Xu L, Simoens C, et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018;5:CD009069.PubMedGoogle Scholar
  3. 3.
    World Health Organization. Human papillomavirus vaccines WHO position paper. Wkly Epidemiol Rec. 2009;85:118–31. http://www.who.int/wer/2009/wer8415.pdf. Accessed 27 May 2018.
  4. 4.
    Crosbie EJ, Einstein MH, Franceschi S, et al. Human papillomavirus and cervical cancer. Lancet. 2013;382:889–99.CrossRefGoogle Scholar
  5. 5.
    Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244–65.CrossRefGoogle Scholar
  6. 6.
    de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13:607–15.CrossRefGoogle Scholar
  7. 7.
    International Agency for Research on Cancer (IARC). GLOBOCAN 2018: cervical cancer estimated incidence, mortality and prevalence worldwide in 2018. 2018. http://gco.iarc.fr/today/explore. Accessed 27 December 2018.
  8. 8.
    Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol. 2004;4:46–54.CrossRefGoogle Scholar
  9. 9.
    Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9.CrossRefGoogle Scholar
  10. 10.
    Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372:711–23.CrossRefGoogle Scholar
  11. 11.
    Read TR, Hocking JS, Chen MY, et al. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2011;87:544–7.CrossRefGoogle Scholar
  12. 12.
    Drolet M, Benard E, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15:565–80.CrossRefGoogle Scholar
  13. 13.
    Brotherton JM, Winch KL, Bicknell L, et al. HPV vaccine coverage is increasing in Australia. Med J Aust. 2017;206:262.CrossRefGoogle Scholar
  14. 14.
    Brotherton JM, Gertig DM, May C, et al. HPV vaccine impact in Australian women: ready for an HPV-based screening program. Med J Aust. 2016;204:184–e1.CrossRefGoogle Scholar
  15. 15.
    Rana MM, Huhtala H, Apter D, et al. Understanding long-term protection of human papillomavirus vaccination against cervical carcinoma: cancer registry-based follow-up. Int J Cancer. 2013;132:2833–8.CrossRefGoogle Scholar
  16. 16.
    Lehtinen M, Lagheden C, Luostarinen T, et al. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of three cohorts from randomized trials. BMJ Open. 2017;e015867:7.Google Scholar
  17. 17.
    Luostarinen T, Apter D, Dillner J, et al. Vaccination protects against invasive HPV-associated cancers. Int J Cancer. 2018;142:2186–7.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Xavier Bosch José
    • 1
    • 2
    • 3
  1. 1.Cancer Epidemiology Research Program, Catalan Institute of OncologyBarcelonaSpain
  2. 2.Epidemiology, Public Health, Cancer Prevention and Palliative Care Program at IDIBELLBarcelonaSpain
  3. 3.Bellvitge Biomedical Research Institute, Hospital Duran i ReynalsBarcelonaSpain

Personalised recommendations